Back to search
FDAFDA · Food and drugs·Recall number D-0510-2023

Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 0093-7487-56, Packet NDC 0093-7487-19

Published April 12, 2023 · Recall initiated: March 27, 2023

Summary

FDA records drug Class III recall D-0510-2023, published April 12, 2023 and initiated March 27, 2023. Recalling firm: Teva Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 3,772 cartons; Lot: Lot # 3007556A, Exp 5/2023. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA Inc
Distributor
USA Nationwide
Lot
Lot # 3007556A, Exp 5/2023
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 0093-7487-56, Packet NDC 0093-7487-19 recalled?

Yes. FDA published recall D-0510-2023 on April 12, 2023. Reported hazard: Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.

What should I do if I have this product?

Voluntary: Firm initiated · Letter